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ORIGINAL ARTICLE

Quercetin blocks the aggressive phenotype of
triple-negative breast cancer by inhibiting IGF1/
IGF1R-mediated EMT program
Wei-Jen Chen a,b,*, Jie-Heng Tsai c, Li-Sung Hsu d,e, Chih-Li Lin e,f,
Hui-Mei Hong a,b, Min-Hsiung Pan g,h,i,**
a

Department of Biomedical Sciences, Chung Shan Medical University, Taichung, 402, Taiwan
Department of Medical Research, Chung Shan Medical University Hospital, Taichung, 402, Taiwan
c
School of Nutrition and Health Sciences, College of Public Health and Nutrition, Taipei Medical University, Taipei, 110, Taiwan
d
Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, 402, Taiwan
e
Clinical Laboratory, Chung Shan Medical University Hospital, Taichung, 402, Taiwan
f
Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan
g
Institute of Food Science and Technology, National Taiwan University, Taipei, 106, Taiwan
h
Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, 40402, Taiwan
i
Department of Health and Nutrition Biotechnology, Asia University, Taichung, 41354, Taiwan
b

Abstract
The cancer-preventive activities of quercetin have been extensively studied in invasive breast cancer; however, the role
of quercetin on triple-negative breast cancer (TNBC) with overexpression of insulin-like growth factor-1 receptor
(IGF1R) has not been resolved. In this article, we demonstrated that quercetin inhibited the activation of IGF1R and its
downstream kinases Akt and Erk1/2 in a dose-dependent manner in human MDA-MB-231 breast cancer cells (TNBC cell
line). Related to this, quercetin markedly suppressed the metastatic phenotype and epithelialemesenchymal transition
(EMT) of MDA-MB-231 cells by inhibiting the expression of EMT transcription factors Snail and Slug. Quercetin also
increased the secretion of IGF-binding protein-3 in the conditioned medium of MDA-MB-231 cells while reducing the
secretion of IGF1; thus, quercetin interrupted the autocrine or paracrine loop of IGF1 signaling. In xenograft mouse
models, the administration of quercetin blocked the growth of MDA-MB-231 tumor xenografts and their lung metastasis,
accompanied by the inactivation of IGF1R and the downregulation of the expression of Snail, Slug, and mesenchymal
markers ﬁbronectin and vimentin. These results suggest that quercetin has cancer-preventive value for TNBC by
inhibiting IGF1/IGF1R signaling and preventing the consequent EMT and metastasis of TNBC.
Keywords: Quercetin, MDA-MB-231 cells, IGF1R, IGF1, EMT

1. Introduction

A

bout 15% to 20% of patients with breast
cancer are diagnosed as triple-negative
breast cancer (TNBC) phenotype, which is characterized by the lack of the expression of estrogen
receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2
(HER2). TNBC tends to be aggressive and could

be predicted for a substantial association with
relapse and unfavorable outcome [1,2]. Given the
absence of target receptors, TNBC is resistant to
current hormone therapy and HER2-targeted
therapy and has been considered a clinical challenge [3]. Therefore, developing new effective
chemotherapeutics or targeted therapies for the
treatment of advanced TNBC is urgently needed.
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Recent epidemiological evidences suggest that
elevated levels of circulating insulin-like growth
factor-1 (IGF1) are highly linked to the increased
recurrence and risk of all-cause mortality in female
breast cancer [4e6]. The overexpression or high
activation of IGF1 or IGF1 receptor (IGF1R) increases cancer incidence and progression with
reduced response to treatment and survival rate
because the IGF1 signaling pathway is involved in
cell proliferation, adhesion, and anchorage-independent growth, which eventually result in cancer
cell invasion and metastatic spreading [7]. About
22% to 46% of TNBCs overexpress IGF1R protein
[8], and the IGF1/IGF1R signaling pathway, which
increases cell proliferation and promotes cell survival, may be active in TNBC cell lines [9]. TNBC cell
lines and xenografts with high IGF1R and IGF1Rinduced gene expression are more sensitive to antiIGF1R therapy in combination with docetaxel [10].
These ﬁndings indicate that IGF1/IGF1R may act as
a prospective anticancer candidate for targeted
therapy in patients suffering from TNBC [11].
IGF1R is a typical receptor of tyrosine kinase and
can transmit signals from insulin receptor substrate1 (IRS1) and Src homology 2-containing protein
(SHC). Activated IRS1 recruits phosphoinositide 3kinase (PI3K) to activate the PI3KeAkt signaling
pathway whereas SHC initiates the mitogen-activated protein kinase (MAPK) signaling cascade to
promote cell proliferation and survival [12].
Furthermore, IGF1R signaling also plays a critical
role in the initiation of invasion and metastasis and
consequent cancer mortality through the induction
of epithelialemesenchymal transition (EMT) program [13]. EMT is a process of trans-differentiation
that endows cancer cells with mobile and cancer cell
stem-like phenotypes during tumor dissemination
[14e16]. EMT-relevant changes in cell polarity and
motility are accompanied by the loss of expression
or mislocalization of cell junction proteins, such as
E-cadherin, zonula occludens (ZO-1), keratin 18,
and keratin 19, and the acquisition of the expression
of mesenchymal-like proteins, such as ﬁbronectin
and vimentin [17]. IGF1 triggers the EMT program,
which results in metastasis in breast, lung, gastric,
and prostate cancers [18e24]. The overexpression of
IGF1R leads to the depolarization and mesenchymal-like transition of breast carcinoma cells in
response to IGF1 [19]. The PI3KeAkt and MAPK
pathways promote IGF1-stimulated EMT progression by upregulating EMT transcription factors,
such as zinc ﬁnger E-box binding homeobox (ZEB)1
and ZEB2 [22,24], or stabilizing EMT transcription
factor Snail by the inactivation of glycogen synthase
kinase-3b (GSK-3b) [25]. These ﬁndings provide
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molecular basis for new drug development by targeting IGF1R signaling pathways.
Quercetin (3,30 ,40 ,5,7-pentahydroxy-ﬂavone), a
naturally occurring ﬂavonoid, is a dietary antioxidant
with substantial anti-bioﬁlm, anti-tumor, antiallergic, and anti-inﬂammatory activities [26,27].
Quercetin has cancer chemopreventive activity in
colon, prostate, and lung cancers and exerts antimetastatic effect on breast cancer [28,29]. Quercetin
can inhibit a broad range of protein kinases,
including PI3K, and is the basis for the structural
design of the synthetic PI3K inhibitor LY294002
[30,31]. In H-Ras-transformed MCF10A cells, quercetin potently blocks H-Ras-induced invasion and
migration by directly inhibiting PI3K activity and
thereby suppressing the activity of matrix metalloproteinase (MMP)2 and MMP9 [28]. Quercetin can
inhibit cell proliferation and EMT or induce
apoptosis in different cancer cells by modulating the
cell signaling pathways elicited by IGF1, hepatocyte
growth factor, and epidermal growth factor (EGF)
[32,33]. In addition, Srinivasan et al. reported that
quercetin reverses EMT and suppresses the migratory ability of TNBC by preventing the nuclear
localization of b-catenin [34]. However, whether
quercetin regulates the IGF1R signaling pathway to
inhibit EMT and the metastasis of TNBC remains
unclear. Thus, we used a TNBC cell line, human
MDA-MB-231 cells, to determine whether quercetin
suppresses the invasive phenotypes in MDA-MB-231
cells by mediating the IGF1/IGF1R signaling
pathway and also validated the underlying mechanisms by cell-based and xenograft animal models.

2. Materials and methods
2.1. Materials
Recombinant human IGF1 and IGF-binding protein-3 (IGFBP3) were obtained from PeproTech, Inc.
(Rocky Hill, NJ). Quercetin, 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium
bromide
(MTT),
dimethyl sulfoxide (DMSO) and Bouin's solution
were obtained from Sigma Chemical Co. (St. Louis,
MO). Snail and Slug siRNAs were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). 40 ,6Diamidino-2-phenylindole (DAPI) was purchased
from Southern Biotech (Birmingham, AL). Picropodophyllin (PPP) was available from MedChem
Express (Monmouth Junction, NJ).
2.2. Cell culture and treatment
Two human breast cancer cell lines MCF-7 (a
luminal A breast cancer cell line with ER and PR
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expression) and MDA-MB-231 (a TNBC cell line)
characterized as low and high metastatic phenotypes, respectively, were purchased from American
Type Culture Collection. Both breast cancer cell
lines were grown in Dulbecco's minimal essential
medium (DMEM) containing 10% fetal bovine
serum (FBS; Gibco BRL, Grand Island, NY), 100
units/mL of penicillin, and 100 mg/mL of streptomycin (Gibco BRL, Grand Island, NY) and incubated in a humidiﬁed atmosphere at 37  C with 5%
CO2. For experiments, cells were harvested from
the culture monolayers at 80%e90% conﬂuence
and then rinsed with cold phosphate-buffered saline (PBS). Viable cells were isolated using 0.25%
trypsin containing 0.1% EDTA, centrifuged at 1000
rpm for 5 min, and then resuspended in growth
medium. Finally, the cells were subcultured and
then processed as described in the following
sections.

secreted protein in the condition medium, MDAMB-231 cells (5  105 cells/mL) were treated with
the indicated quercetin for 24 h, and the protein
concentration in the condition medium was
measured by the Bradford method to ensure that
the load in the Western blot was equal.

2.3. Western blot

MDA-MB-231 cells (2.5  104) were plated in the
upper chamber of a Corning Transwell (cat. no.
3422, Corning Incorporated, New York, NY) with
polycarbonate ﬁlm (8-mm pores) covered with
Matrigel (BD Biosciences, San Jose, NJ) in DMEM
containing 0.5% FBS at 37  C. After treatment with
quercetin, the cells remaining in the upper side of
the membrane were scraped off with a cotton swab.
The number of cells that invaded the lower surface
of the membrane was visualized by propidium iodide staining and counted in at least ﬁve random
ﬁelds using a ﬂuorescence microscope (Carl Zeiss
MicroImaging GmbH, Jena, Germany).

After treatment with various concentrations of
quercetin as indicated in the ﬁgure legends, cell
lysates were prepared by incubating the harvested
cells with a homobuffer (50 mM Tris-HCl [pH 8.0], 5
mM EDTA, 150 mM NaCl, 0.5 mM phenylmethanesulfonylﬂuoride, 0.5 mM dithiothreitol, and
0.5% NP-40) for 30 min at 4  C. Then 50 mg of the
total cellular proteins of each sample were subjected
to sodium dodecyl sulfateepolyacrylamide gel
electrophoresis and transferred onto polyvinylidene
diﬂuoride membranes (Immobilon P, Millipore,
Billerica, MA). Western blot was performed by incubation with primary antibodies followed by
horseradish peroxidase (HRP)-conjugated secondary antibodies. The immune complexes were
stained with enhanced chemiluminescence kits
(Amersham, UK), and band density was calculated
using a Fujiﬁlm LAS-4000 luminescent image
analyzer (Fujiﬁlm UK Ltd., Bedford, UK). Antibodies
against IGF1, IGF1R, phospho-IRS1 (Ser307), IRS-1,
phospho-Akt (Ser 473), Akt, phospho-Erk1/2 (Thr
202/Tyr 204), Erk1/2, vascular endothelial growth
factor (VEGF), ZO-1, Oct4, Sox2, and Nanog were
purchased from Cell Signaling Technology (New
England Biolabs, Ipswich, MA). Antibodies against
E-cadherin and vimentin were purchased from
Millipore (Billerica, MA). IGFBP3, Snail, Slug, and
phospho-IGF1R (Tyr 1161) antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). bActin antibody was sourced from Sigma Chemical
(Sigma, St. Louis, MO). In order to determine the

2.4. Wound healing assay
A linear wound was created on the cultured cell
monolayer with approximately 90% conﬂuence
using a sterile 200 mL micropipette tip. Then, the
cells were rinsed with cold PBS to remove the detached cells and re-cultured in 1% FBSeDMEM.
The cells were treated with a variety of concentrations of quercetin for 24 h, and the closure of wound
edge was measured with a microscope.
2.5. In vitro invasion assay

2.6. Cell adhesion assay
Cell adhesion assay was performed based on a
colorimetric method, in which extracellular matrix
(ECM)-adherent cells are stained with crystal violet
dye. Brieﬂy, a 6-well plate was coated with 10 mg/mL of
collagen or 20 mg/mL of ﬁbronectin for 1 h at 4  C and
then blocked with 1% bovine serum albumin in
DMEM for 1 h before seeding. Then, MDA-MB-231
cells pretreated with quercetin for 24 h at a density of 1
 105 cells were plated in ﬁbronectin-coated plate by
incubation with 10% FBS-containing DMEM at 37  C
for 1 h. After washing with PBS to remove nonattached cells, the adherent cells were ﬁxed using 70%
ethanol, stained with 0.1% crystal violet, and then
visualized using a microscope (magniﬁcation 200
times). The stain of the adherent cells was extracted in
0.2% Triton X-100 and further quantiﬁed colorimetrically by measuring the absorbance at 550 nm.

2.7. Immunoﬂuorescence staining
MDA-MB-231 cells were seeded on coverslips to
60% conﬂuence and then treated with various concentrations of quercetin for 24 h. For F-actin staining, the cells were washed with cold PBS, ﬁxed with
4% paraformaldehyde for 20 min at room temperature, and labeled with Alexa Fluor 488-conjugated
Phalloidin (Molecular Probes, Eugene, OR)
(1:10,000). For immunoﬂuorescence staining, the
cells were ﬁxed with 4% paraformaldehyde; immunolabeled with primary antibody, such as mouse
monoclonal anti-vimentin, anti-ﬁbronectin (Santa
Cruz Biotechnology, CA), and anti-keratin 18 or
anti-keratin 19 (Cell Signaling Technology, Danvers,
MA), at 4  C overnight in the dark; incubated with
secondary antibodies, including rabbit anti-mouse
secondary antibody conjugated with ﬂuorescein
isothiocyanate (FITC; Sigma, St. Louis, MO) for 30
min at room temperature. The cells were then
mounted with DAPIeFluoromount-G (Southern
Biotech, Birmingham, AL), and their ﬂuorescent
images were observed using a ﬂuorescence microscope (Carl Zeiss MicroImaging GmbH, Jena,
Germany).
2.8. Cell viability assay
Breast cancer cells with a density of 5  103 cells/
mL were grown overnight in a 96-well plate and
then treated with various concentrations of quercetin for 24 h. After incubation, the cell viability was
determined by the following MTT assay method. 20
mL of MTT solution (5 mg/mL) was added to each
well and incubated for 30 min at 37  C. Then the
supernatant was discarded, the MTT-formazan
crystals formed by the metabolism of living cells
were dissolved in 200 mL DMSO and the absorbance
of the dissolved crystals at a wavelength of 570 nm
was measured by the colorimetric method.
2.9. Quantitative reverse transcription-polymerase
chain reaction (Q-PCR)
Total RNA was extracted using TRIzol reagent
(Sigma, St. Louis, MO) according to the manufacturer's instructions. Brieﬂy, total RNA (5 mg) was
reverse-transcribed into cDNA by incubating with
the reaction mixture (25 mL) for 90 min at 40  C using
Moloney murine leukemia virus (MMLV) reverse
transcriptase with oligo-dT18 primer. The sequences of the forward and reverse primers used
are listed in Table 1. Q-PCR was performed in a
ﬁnal volume of 20 mL using an optimized concentration of each primer pair with the Fastart
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Universal SYBR Green Master Mix (Roche, Indianapolis, IN), and the products were analyzed with an
ABI 7000 sequence detection system.
2.10. Luciferase assay
The promoter regions of Snail (350 to þ1126)
and Slug (450 to þ1035) were cloned into a yT&A
vector (Yeastern Biotech, Taiwan) according to the
procedure described by Chen Y. et. al. [35]. The
upstream regions of Snail (350 to þ84) and Slug
(450 to þ164) were subsequently cloned into a
ﬁreﬂy luciferase expression vector (pGL3; Promega, Madison, WI). Then, 30 ng of pGL3-basic,
pGL3-Snail promoter, or pGL3-Slug promoter
vectors were co-transfected with 30 ng of bgalactosidase expression vector (pCH110, internal
control vectors; Addgene, Watertown, MA) into
MDA-MB-231 cells (at a density of 5  104 cells
per well in 6-well culture plate) using a Turbofect
kit (Fermentas, Carlsbad, CA) following the manufacturer's instructions. After 16 h of transfection,
the cells were exposed to quercetin (0, 5, 10, and
20 mM) for an additional 24 h. Cell lysates were
then collected and assayed for normalized luciferase activity using a luciferase assay kit (Promega, Madison, WI).
2.11. Animal care and xenograft study
All procedures in the animal experiments were
approved by Taiwan University's Institutional Animal Care and Use Committee. Brieﬂy, 4-week-old
female SCID mice were purchased from BioLASCO
Experimental Animal Center (Taiwan Co., Ltd.).
After 1 week of adaptation, the abdominal hair of
each mouse was shaved the day before the start of
the experiment. 5-Week-old mice were injected with
MDA-MB-231 cells (2  106 cells/0.1 mL Hanks'
balanced salt solution) into the bottom left mammary fat pad. After 3 days of transplantation, the
mice were randomly divided into two groups: control group and experimental group. Each group had
six mice. The mice were injected intraperitoneally
(i.p.) with an aliquot of corn oil (control group) or
with 20 or 50 mg/kg quercetin (experimental group)
ﬁve times per week for 42 days. Then, the mice were
sacriﬁced for further histological and immunohistochemical studies as described below.
2.12. Histological analysis
For histological studies, the lung tissues were
preserved in 10% neutral buffered formalin and
embedded in parafﬁn. Then, the parafﬁn-embedded
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Table 1. Primers for quantitative RT-PCR and cloning snail and slug promoters.
Gene
symbol
Quantitative qPCR primers
Snail
Slug
Zeb1
GAPDH
Primers for promoters cloning
Snail
Slug

Forward primer (5ʹ to 3ʹ)

Reverse primer (5ʹ to 3ʹ)

GGCGTGTGCTCG GACCTTCT
CCTTCTCCAGAATGTCTCTC
GCACAACCAAGTGCAGAAGA
GAGTCAACGGATTTGGTCGT

AGGCAGGGGCAGGTATGGAG
ATTTGGTTGGTCAGCACAGGAGA
CATTTGCAGATTGAGGCTGA
GACAAGCTTCCCGTTCTCAG

AAGCGCTCAGACCACCGGGC
TTGTGCAAGGCAAACCTCTC

GGGAAGAGACTGAAGTAGAGGAGA
GTATGACAGGCATGGAGTAACTCTC

tissues were cut into 4 mm-thick sections and stained
with hematoxylin and eosin. Histological patterns
were observed using a microscope.

0.05% 3,30 -diaminobenzidine tetrahydrochloride,
and observed under a light microscope.
2.14. Statistical analysis

2.13. Immunohistochemistry (IHC)
The 3-mm tumor sections were deparafﬁnized and
rehydrated by treatment with 3% hydrogen
peroxide for 15 min to block endogenous peroxidase. The sections were cooked under pressure in 10
mM citrate buffer at pH 6.0 (ImmunoDNA retriever
citrate, BIO SB, Santa Barbara, CA) for antigen
retrieval. The sections were then incubated with
primary antibody against phospho-IGF1R (pIGF1R),
IGF1R, Snail, vimentin, keratin 18 and keratin 19
(diluted 1:200 in PBS) overnight and incubated with
biotinylated secondary antibody for 30 min. The
tissue sections were further reacted with
streptavidineHRP for 30 min, then colored with

Experimental data were obtained via three or
more repeated experiments and expressed as mean
± standard error of the mean (SEM). One-way
ANOVA post hoc Tukey's b test was used to evaluate multiple comparison, and the test was considered signiﬁcantly different when p < 0.05.

3. Results
3.1. Quercetin inhibits the activation of IGF1R and
its downstream signaling pathways in MDA-MB231 cells
The expression and phosphorylation status (activation) of IGF1R and its related downstream

Fig. 1. Downregulation of IGF1R phosphorylation and its downstream signaling by quercetin in MDA-MB-231 cells. MDA-MB-231 cells were
treated with the indicated concentrations of quercetin for 24 h. (A) Effect of quercetin on the phosphorylation status of IGF1R and IRS1 was
determined by Western blot. (B) The phosphorylation status of two main IGF1R-downstream signaling kinases, AKT and ERK, was also analyzed by
Western blot. (C) The secretion of IGFBP3 and IGF1 proteins in conditioned medium were monitored by Western blot in quercetin-treated MDA-MB231 cells. b-Actin was used as internal control in Western blot, and all data are the mean of at least three measurements..
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Fig. 2. Inhibition of the aggressive invasion phenotypes of MDA-MB-231 cells by quercetin. (A) Wound healing assay was performed by treatment
with the indicated doses of quercetin for 24 h in MDA-MB-231 cells after scraping a 90% conﬂuent culture into a wound. (B) After 90% conﬂuent
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signaling molecules, including IRS1, Akt, and Erk1/
2, were examined by Western blot to elucidate
whether quercetin affects the IGF1R-mediated
signaling in MDA-MB-231 cells. As shown in Fig.
1A, quercetin reduced the phosphorylation statuses
of IGF1R and IRS1 in a dose-dependent manner
while downregulating the phosphorylation statuses
of Akt and Erk1/2 (Fig. 1B). Quercetin also reduced
IGF1 secretion in conditioned medium in a concentration-dependent manner but increased the
accumulation of IGFBP3 (Fig. 1C). These results
indicate that quercetin can downregulate IGF1Rmediated signaling, which is correlated with the
reduced autocrine/paracrine action of IGF1 in
MDA-MB-231 cells.
3.2. Quercetin suppresses the invasive phenotypes
of MDA-MB-231 Cells
A scratch wound healing assay was performed to
decipher the effect of quercetin on cell motility to
assess whether the suppression of IGF1R signaling
by quercetin is tightly correlated with the downregulation of the invasive phenotypes of MDA-MB231 cells. Fig. 2A displays that quercetin remarkably
exhibited a dose-related delay in wound healing
after 24 h of incubation with 1% FBS in MDA-MB231 cells. Fig. 2B shows that IGF1R was overexpressed in MDA-MB-231 cells compared with MCF7 cells and IGF1 has the ability to drive the wound
healing of MDA-MB-231 cells but has no substantial
effect on the wound healing of MCF-7 cells. This
result demonstrated that IGF1/IGF1R signaling is
essential for the wound closure of MDA-MB-231
cells. Then, invasion assay using Matrigel-coated
Transwell was performed to evaluate the effect of
quercetin on the invasive ability of MDA-MB-231
cells. The result showed that quercetin caused a
concentration-dependent decrease in Transwell invasion cells with a reduction from ~20% to ~64% in
response to quercetin treatment (Fig. 2C). Fig. 2C
(lower panel) displayed that picropodophyllin
(PPP), a selective IGF1R inhibitor, suppressed the
Transwell invasion of MDA-MB-231 cells, indicating

that IGF1R signaling can drive the invasion of
MDA-MB-231 cells. In addition, the culture dishes
were pre-coated with type I collagen or ﬁbronectin,
and the degree of cell adhesion was evaluated by
colorimetry to verify whether quercetin affects cell
adhesion. The data show that quercetin remarkably
reduced the MDA-MB-231 cells that adhered to the
tested ECM in a dose-dependent manner (Fig. 2D).
In order to rule out that the anti-invasive effect of
quercetin in MDA-MB-231 cells was due to the
cytotoxicity of quercetin, the cell viability in MDAMB-231 cells treated with quercetin was determined
by MTT method. Fig. 2E shows that quercetin
slightly inhibited the proliferation of MDA-MB-231
cells at low concentrations (<25 mM), but the degree
of inhibition was remarkably lower than that of
quercetin on motility and invasiveness (Fig. 2A and
C, respectively). Meanwhile, we also determined the
cytotoxic effect of quercetin on MCF-10A cell line
(non-tumorigenic breast epithelial cells) and Hs578t
cell line (TBNC) by MTT assay to evaluate the biological safety of quercetin. We found that quercetin
has a low growth inhibitory effect on MDA-MB-231,
Hs578t and MCA-10A cells, and the IC50 of all cells
exceeds 100 mM. In particular, non-carcinogenic
MCF-10A cells are more resistant to quercetin than
the two TNBC cell lines MDA-MB-231 and Hs578t
cells, which indicates that quercetin is selective
against TNBC and suggested to be less toxic to
normal cells. Taken together, the results conﬁrmed
that the inhibition of IGF1R signaling by quercetin is
closely related to the downregulation of the invasiveness and migration of MDA-MB-231 cells.
3.3. Quercetin reverses the EMT program by the
acquisition of cancer stem cell-like (CSCL)
phenotype in MDA-MB-231 cells
EMT is considered a prerequisite for IGF1/
IGF1R-induced cancer cell migration and metastatic potential [36]. The expression levels of EMT
markers were monitored by Western blot in
quercetin-treated MDA-MB-231 cells to explore
whether the downregulation of IGF1R signaling

cells were scraped with a pipette tip to produce a wound, the cells were incubated with IGF1 (50 ng/mL) for 24 h, and the images of the wound were
further examined using a microscope. The quantiﬁed data represent the relative distance of the wound width, which is expressed as the measured
wound width divided by the width at the beginning of the wound. The left panel represents the expression of IGF1R in MCF-7 and MDA-MB-231
cells determined by Western blot, and b-actin was used as internal control. (C) Invasion assay was performed using a diluted Matrigel-coated
Transwell. After 24 h of cell culture in the upper chamber of the Transwell, the MDA-MB-231 cells were exposed to the indicated concentrations of
quercetin or 200 nM PPP (IGF1R inhibitor) for an additional 24 h. The gel-invading cells on the lower surface of the ﬁlter were stained and quantiﬁed
by microscopy with 10 random ﬁelds per well. (D) MDA-MB-231 cells pretreated with quercetin for 24 h were cultured in 24-well plates coated with
10 mg/mL of collagen or 20 mg/mL of ﬁbronectin for 1 h. Adherent cells were counted by colorimetry using a microscope. (E) The indicated cell lines
were treated with 0, 25, 50, or 100 mM quercetin for 24 h and cell viability was measured using a MTT-based method. All quantiﬁed data was derived
from the statistics of at least three repeated experiments and expressed as mean ± SEM. Signiﬁcant difference compared with the control group was
signed as asterisks (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
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Fig. 3. Reversal of EMT and inhibition of expression of CSCL markers by quercetin in TNBC cell lines. (A) MDA-MB-231, Hs578t and HCC38 cells
were treated with quercetin in the quantiﬁed dose for 24 h, and the protein expression of EMT markers was examined by Western blot. (B)
Immunoﬂuorescence by probing F-actin with Alexa Fluor 488 phalloidin (green) or by labeling vimentin, ﬁbronectin, keratin18, or keratin19 with
secondary antibody conjugated with FITC (green). Nuclei were stained with DAPI (blue). (C) The expression of Oct4, Sox2, and Nanog in MDA-MB231 cells were determined by Western blot after 24 h of quercetin treatment. b-Actin was used as internal control. All of the measurements were
performed at least three times.

pathway and the invasive phenotype of MDA-MB231 cells by quercetin are accompanied by EMT
reversal. Fig. 3A shows that the protein levels of
mesenchymal markers, including vimentin, ﬁbronectin, and VEGF, decreased in a dose-dependent
manner in quercetin-treated cells. By contrast, the
protein levels of epithelial-like markers, such as
keratin 18, keratin 19, and ZO1, increased in a
dose-dependent manner after quercetin treatment. Quercetin also dose-dependently inhibited
the protein expression of vimentin in the other
two TNBC cell lines Hs578t and HCC38, demonstrating that the inhibition of quercetin on EMT of
TNBC cells is universal, not only for MDA-MB231 cells (Fig. 3A). Moreover, immunoﬂuorescence
staining revealed that the high concentration of
quercetin reduced the formation of stress ﬁbers
assembled by F-actin and induced the localization
of F-actin at the cell junction (Fig. 3B). Consistent
with Fig. 3A, immunoﬂuorescence images show

that quercetin decreased the protein levels of
vimentin and ﬁbronectin and increased the protein levels of keratin 18 and keratin 19 in MDAMB-231 cells (Fig. 3B). The EMT program confers
metastasis to cancer cells and promotes the
development of cancer cells into an undifferentiated state with drug resistance, which are
possessed by stem cells [37]. We further investigated whether the decrease in mesenchymal-like
phenotype caused by quercetin is correlated with
a possible decrease in the stemness of the
phenotype of MDA-MB-231 cells. We assessed the
expression of embryonic stem cell transcription
factors Oct4, Sox2, and Nanog by Western blot
and found that quercetin diminished the expression of Oct4, Sox2, and Nanog in a concentrationdependent manner (Fig. 3C), which was accompanied by the reversal of EMT and the suppression of the invasion phenotype in MDA-MB-231
cells. These ﬁndings implicated that quercetin
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Fig. 4. Effects of quercetin on the expression of Snail and Slug required for EMT in MDA-MB-231 cells. (A) After 24 h of exposure to quercetin, the
protein and mRNA expression levels of Snail and Slug in the indicated breast cancer cells were monitored by Western blot (left panel) and Q-PCR
(right panel), respectively. The relative mRNA level of Snail or Slug is expressed as the measured transcript level divided by glyceraldehyde 3phosphate dehydrogenase's transcript level. (B) The pGL3-Snail or pGL3-Slug promoter vector was co-transfected into MDA-MB-231 cells for 16 h
with the b-galactosidase reporter vector. Then, the transfected cells were treated with the indicated concentration of quercetin for 24 h. Snail or Slug
promoter activity was determined by luciferase reporter assay and normalized to b-galactosidase activity. (C) MDA-MB-231 cells were transfected
with siRNA against Snail or Slug for 24 h. The expression of Snail and Slug was analyzed by Western blot. (D) The effect of Snail or Slug siRNAs on
the expression of epithelial markers (keratin18, keratin 19, and ZO-1), and mesenchymal markers (vimentin, ﬁbronectin, and VEGF) was monitored
by Western blot. (E) Fifty-percent conﬂuent MDA-MB-231 cells were incubated for 12 h under serum-free conditions. The cells were pretreated with
20 mM quercetin (Que) or 200 nM PPP for 30 min, then stimulated with IGF1 (50 ng/mL) for 18 h and subjected to Western blot to analyze the
expression of Snail and Slug. All data measurement were performed at least three times and considered signiﬁcantly different compared with the
control group (*, p < 0.05; **, p < 0.01; ***, p < 0.001).
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Fig. 5. Antitumor and anti-metastatic activity of quercetin in MDA-MB-231 xenograft mouse model. Female SCID mice were transplanted with
MDA-MB-231 cells (2  106 cells) in the mammary fat pad and treated with quercetin (20 or 50 mg/kg, i.p.) for 42 days. (A) Tumor weight was
measured after 42 days of quercetin treatment. Data are expressed as mean ± SEM (n ¼ 6). *p < 0.05 and **p < 0.01 present that quercetin
administration is signiﬁcantly different from the vehicle control. (B) The lungs were removed at 42 days and ﬁxed with 10% neutral buffered formalin
for 24 h. The overall appearance of the pulmonary nodules was observed under a light microscope after hematoxylin and eosin staining (Scale bar ¼
100 mm). (C) Xenograft tumor tissues were removed and ﬁxed with 10% formalin for 24 h. The expression of indicated proteins was determined in
triplicate by IHC in xenograft tumor specimens (Scale bar ¼ 100 mm).
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Fig. 6. Inhibitory effects of quercetin on IGF1R signaling and the consequent EMT and invasion in MDA-MB-231 cells and xenograft mouse model.

leads to the reversal of EMT in MDA-MB-231
cells.
3.4. Quercetin downregulates the expression of
Snail and Slug transcription factors required to
maintain the mesenchymal phenotype of MDAMD-231 cells
EMT-driven transcription factors, such as Snail
and Slug, orchestrate EMT and induce breast cancer
entrance into the tumor-initiating and metastatic
states [38]. The expression of Snail and Slug was
veriﬁed in quercetin-treated MDA-MB-231 cells to
further demonstrate whether quercetin affects the
EMT proﬁle of MDA-MB-231 cells through a Snailor Slug-dependent mechanism. As shown in Fig.
4A, quercetin dose-dependently inhibited the protein and mRNA expression of Snail and Slug in
MDA-MB-231 cells. Quercetin also inhibited the
protein expression of Snail and Slug in Hs578t cells
in Fig. 4A (bottom left). Consistently, quercetin
markedly inhibited Snail and Slug promoter activities in MDA-MB-231 cells in a concentrationdependent fashion (Fig. 4B). Relative siRNA was
applied to silence the expression of Snail and Slug
in MDA-MB-231 cells to explore whether Snail and
Slug are essential for the EMT of MDA-MB-231
cells. Fig. 4C demonstrates that speciﬁc siRNA
transfection efﬁciently inhibited the protein
expression of Snail and Slug. In parallel, the

expression of epithelial markers keratin 18, keratin
19, and ZO1 was upregulated, whereas the expression of mesenchymal markers vimentin, ﬁbronectin,
and VEGF was downregulated in Snail or Slug
siRNA-transfected MDA-MB-231 cells (Fig. 4D). The
protein levels of these two EMT transcription factors
were determined by Western blot in IGF1-stimulated cells to further verify whether IGF1/IGF1R
signaling is responsible for Snail and Slug expression in MDA-MB-231 cells. Fig. 4E also shows that
IGF1 dramatically triggered the Snail and Slug
expression, and that quercetin and PPP can inhibit
IGF1-stimulated Snail and Slug expression in MDAMB-231 cells. Overall, these results suggest that
quercetin inhibited the EMT and aggressive
phenotype of MDA-MB-231 cells by blocking IGF1/
IGF1R-mediated Snail and Slug expression.
3.5. Quercetin suppresses xenograft tumor growth
and metastasis by suppressing IGF1R signaling
pathway and inducing EMT reversal in vivo
MDA-MB-231 cells were implanted into the
mammary fat pad of female SCID mice with an i.p.
injection of 20 or 50 mg/kg quercetin to elucidate
whether quercetin blocks IGF1-induced invasion
and metastasis in vivo. No detectable toxicity and
weight loss were observed in mice after the
administration of quercetin (data not shown). In
addition, the transplanted mice showed no signs of

adverse health effects and pain. After 42 days of
quercetin administration, the mice were sacriﬁced
to assess tumor weight and the extent of breast
cancer metastasis in the lungs. Fig. 5A exhibits that
quercetin treatment at the dosages of 0, 20, and 50
mg/kg gradually reduced xenograft tumor weights
to 1.696 ± 0.184, 1.358 ± 0.398, and 0.934 ± 0.257 g,
respectively. The histological examination of the
overall appearance of the pulmonary nodules after
ﬁxation and hematoxylin and eosin staining
revealed that quercetin markedly decreased the
degree of pulmonary nodules and lung metastases
in xenograft mice (Fig. 5B). As expected, quercetin
downregulated the expression of pIGF1R; IGF1R;
and mesenchymal-like markers, such as Snail, Slug,
ﬁbronectin, and vimentin, and conversely upregulated the expression of epithelial-like markers, such
as keratin 18 and keratin 19, in xenograft tumor
tissues (Fig. 5C). The results suggest that quercetin
prevented the xenograft tumors from undergoing
EMT by inhibiting IGF1R signaling and reversing
EMT program; therefore, metastasis was inhibited
in vivo (see Fig. 6).

4. Discussion
Despite our understanding of the highly aggressive and metastatic nature of the triple-negative
subtype of breast cancer, we have yet to develop
truly effective therapies to target this subset of disease. The development of many new therapies is
focused on targeting primary breast tumor [39];
however, the major deaths from TNBC are due to
distant metastasis. Targeting IGF1/IGF1R signaling
has been considered a promising strategy for treating breast cancers, including TNBC, because breast
cancer cells that overexpress IGF-IR exhibit loss of
cell polarity and EMT after IGF1 stimulation [19],
and at least ~22% to 46% of patients with TNBC
have high IGF1R protein expression. In this study,
we demonstrated that quercetin had a negative effect on the invasion and metastasis of MDA-MB-231
cells (Fig. 2) and inhibited IGF1R and its downstream Akt and Erk1/2 activities (Fig. 1A and B).
Additionally, quercetin inhibited xenograft tumor
growth and reduced lung nodules and metastasis in
MDA-MB-231 xenograft mouse model (Fig. 5A and
B). These ﬁndings suggest that such inhibition is
due to the modulation of IGF1/IGF1R signaling by
quercetin to prevent TNBC cells from expanding
their metastatic subpopulation.
A growing number of reports indicate that IGF1mediated PI3KeAkt and MAPK pathways enhance
cancer cell proliferation, invasion, and metastasis by
initiating EMT and modulating MMP activities
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[40,41]. The PI3KeAkt or MAPK pathway enhances
the expression of EMT-resultant transcription factors, such as Snail, Slug, ZEB1, and ZEB2, to promote the induction of EMT and ﬁnally increases the
motility of cancer cells [42,43]. Slug transfectant
enhanced IGF1/IGF1R signaling in an autocrine
manner by increasing the sensitivity of IGF1R to
IGFs [20]. In view of these ﬁndings, our results
showed that IGF1 increased the protein expression
of Snail, and Slug (Fig. 4E), and the knockdown of
Snail and Slug was sufﬁcient to lead to the reversal
of EMT in MDA-MB-231 cells (Fig. 4D). In addition,
our study provides strong evidence that quercetin
has the ability to inhibit the expression of Snail and
Slug (Fig. 4A and B), which is related to the
decreased expression of mesenchymal-related proteins ﬁbronectin and vimentin in MDA-MB-231 cells
(Fig. 3A and B) and xenograft tumors (Fig. 5C). In
fact, some reports have shown that quercetin has an
inhibitory effect on EMT-related diseases. For
example, quercetin inhibits renal tubular EMT and
renal ﬁbrosis induced by mTORC1-mTOR-p70S6K
signaling pathway in diabetic nephropathy [44].
Quercetin inhibits the EGF-induced transcription
activities of Snail, Slug, and Twist by modulating the
PI3KeAkt and Erk1/2 pathways and therefore prevents EMT in PC-3 prostate cancer cells [45].
Quercetin also downregulates the EMT and migration of TNBC by restraining the nuclear localization
of b-catenin [34]. Based on these results, we suggest
that quercetin may prevent the EMT and aggressive
invasion of TNBC cells by blocking IGF1/IGF1Rmediated Snail and Slug expression.
In Fig. 1C, we found that quercetin induced the
secretion level of IGFBP3 in the conditioned medium of MDA-MB-231 cells in a dose-dependent
manner but remarkably reduced the secretion level
of IGF1. Similar results were found in quercetintreated androgen-independent prostate cancer PC-3
cells. Quercetin expands the accumulation of
IGFBP-3 and reduces the level of IGFs in the
conditioned medium of PC-3 cells; these changes
are accompanied by caspase3-dependent apoptosis
[46,47]. Quercetin increases the mRNA expression of
IGFBP3, downregulates IGF1R-mediated signaling
pathways, and therefore induces apoptosis in PC-3
cells [48]. IGFBP3 has multiple effects on tumor
development; it negatively regulates autocrine or
paracrine growth and cancer metastasis by binding
to IGF in the circulation and enhances tumor progression by an IGF1-binding-independent manner
[41]. Dependent of IGF1 binding, exogenous IGFBP3
inhibits the binding of IGFs to receptors by sequestrating IGFs and therefore retards the growth of
breast cancer and several other cancer cells [7]. The
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knockdown of IGFBP3 expression enhances cancer
progression and metastasis at the early stage of
tumor process in mice [49]. Herein, we found that
quercetin reduces the secretion ratio of IGF1 to
IGFBP3 and suppressed the activation of IGF1R,
IRS1, Akt, and Erk1/2 (Fig. 1A and B). These ﬁndings
suggest that quercetin may prevent the autocrine or
paracrine loop of IGF1 signaling and the malignancy
of TNBC by increasing the expression and secretion
of IGFBP3, but the detailed mechanism needs
further investigation.
IGF1R and focal adhesion kinase maintain the
mesenchymal features, CSCL characteristics, and
the invasive phenotypes of TNBCs [50]. 6Bromoindirubin-30 -oxime, a GSK-3b inhibitor, was
able to reduce the EMT program, stem cell-like
propensity, and metastatic behaviors of TNBCs
[51]. These ﬁndings suggest that TNBC can acquire stem cell-like and invasive features by
IGF1R signaling-dependent EMT; thus, its resistance to drug treatment is increased. Here, we
observed that the protein expression of Sox2, Oct4,
and Nanog, the well-identiﬁed transcription factors that maintain the pluripotency of CSCL cells,
was dose-dependently downregulated by quercetin in MDA-MB-231 cells (Fig. 3C), similar to the
inhibition of mesenchymal-like and invasive phenotypes. Thus, we suggest that EMT reversion by
quercetin could make MDA-MB-231 cells welldifferentiated, but this issue requires further
study.
In summary, quercetin was able to reduce the
activation of IGF1R and its downstream kinases Akt
and Erk1/2 and simultaneously decrease Snail and
Slug expression levels in MDA-MB-231 cells,
reverse EMT program, and suppress the invasive
phenotypes of MDA-MD-231 cells. Quercetin also
inhibited IGF1R activation, reduced the expression
levels of mesenchymal markers (Snail, Slug, ﬁbronectin, and vimentin), and upregulated the expression levels of epithelial markers (keratins 18 and 19),
which suppressed the growth of xenograft tumors
and lung metastasis in xenograft mouse experiment.
These results suggest that the anti-EMT and metastatic activity of quercetin on TNBC may be partly
caused by the modulation of IGF1/IGF1R signaling
pathway and point out the application value of
quercetin in the treatment of TNBC.
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